Cantor Fitzgerald Initiates Coverage On ARS Pharmaceuticals with Overweight Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has initiated coverage on ARS Pharmaceuticals with an Overweight rating and set a price target of $30.
August 20, 2024 | 9:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has initiated coverage on ARS Pharmaceuticals with an Overweight rating and a price target of $30, indicating a positive outlook.
The initiation of coverage with an Overweight rating and a $30 price target by Cantor Fitzgerald suggests a positive sentiment towards ARS Pharmaceuticals. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100